Boldenone Undecylenate 250 - Genetic Pharmaceuticals

Boldenone undecylenate was formulated to offer a slow-acting anabolic profile through the attachment of the long undecylenate ester. Developed after Ciba’s patent of boldenone in 1949, it was introduced briefly in the 1960s as Parenabol, targeting conditions like muscle wasting and osteoporosis. However, human use was discontinued by the 1970s. The compound gained pharmaceutical longevity in the veterinary field, especially under Squibb’s Equipoise, where it was used to promote appetite and lean mass in horses.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Boldenone Undecylenate 250 by Genetic Pharmaceuticals, consult with your doctor or healthcare professional.